
    
      Patients identified at the time of presentation to their cardiologist will be asked to
      provide a urine sample for analysis. If blood is being drawn for other clinical tests, an
      extra vial of blood will be collected for measurement of bFGF, VEGF, angiopoietin 1&2 and
      ephrin. At the time of blood draws, approximately 4 cc's of heparin blood will be obtained
      and processed as detailed below. Blood and/or urine samples will be coordinated through the
      data manager and will be performed only when blood is being obtained for other reasons.
      Initially, blood samples will be sent to Lab Control, spun down, and the plasma isolated.
      Plasma will be coded, then frozen at -200C in the research lab. Urine samples will be
      aliquoted into vials and stored at -20 until further analysis.

      All patient information will be kept confidential. Individual results will not be provided to
      patients. Identifiers to patient information will be maintained. No identifying patient
      information will be used in publications that might result from these studies. Information to
      be collected by the data manager will include age, sex, date of diagnosis and interventions.

      The specific aim is to assess angiogenic growth factor concentrations in urine and blood from
      patients with both congenital and acquired multivessel pulmonary vein stenosis.
    
  